Pelthos Therapeutics Inc.
PTHS- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001919246
In the last 90 days, Pelthos Therapeutics Inc. insiders filed 0 open-market purchases and 3 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $38.5M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Pelthos Therapeutics Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- +7 vs. Q1 2026
- Shares held
- 1.36M
- +449.0K (+49.2%) vs. Q1 2026
- Total value
- $38.5M
- +$19.3M (+100.7%) vs. Q1 2026
- New holders
- 10
- 7 more added
- Sold out
- 3
- 2 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PTHS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 24 | $38.5M |
| Q1 2026 | 17 | $19.2M |
| Q4 2025 | 15 | $27.9M |
| Q3 2025 | 14 | $13.0M |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Pelthos Therapeutics Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| AIGH Capital Management LLC | 329,098 | $9.30M | 0.84% | +329,098 | New |
| Murchinson Ltd. | 304,302 | $8.60M | 4.15% | +7,988+2.7% | Added |
| Ikarian Capital, LLC | 256,598 | $7.25M | 1.19% | 00.0% | Unchanged |
| Boothbay Fund Management, LLC | 101,976 | $2.88M | 0.05% | +20,118+24.6% | Added |
| Vanguard Capital Management LLC | 97,134 | $2.75M | 0.00% | +4,041+4.3% | Added |
| Cantor Fitzgerald, L. P. | 76,246 | $2.15M | 0.02% | +34,823+84.1% | Added |
| J. Goldman & Co LP | 38,075 | $1.08M | 0.04% | −12,340−24.5% | Reduced |
| Diadema Partners LP | 24,773 | $700.1K | 0.25% | 00.0% | Unchanged |
| Wexford Capital LP | 22,364 | $632.0K | 0.09% | +22,364 | New |
| Knott David M Jr | 22,073 | $623.8K | 0.33% | +1,000+4.7% | Added |
| Citadel Advisors LLC | 15,046 | $425.2K | 0.00% | +15,046 | New |
| Geode Capital Management, LLC | 14,650 | $414.0K | 0.00% | −640−4.2% | Reduced |
| Pale Fire Capital SE | 12,919 | $365.1K | 0.03% | 00.0% | Unchanged |
| 1492 Capital Management LLC | 10,380 | $293.3K | 0.09% | +10,380 | New |
| Vanguard Fiduciary Trust Co | 9,873 | $279.0K | 0.00% | +56+0.6% | Added |
| State Street Corp | 9,800 | $276.9K | 0.00% | +9,800 | New |
| Persistent Asset Partners Ltd | 6,007 | $169.8K | 0.05% | 00.0% | Unchanged |
| BlackRock, Inc. | 5,324 | $150.5K | 0.00% | +5,324 | New |
| UBS Group AG | 2,217 | $62.7K | 0.00% | +1,453+190.2% | Added |
| China Universal Asset Management Co., Ltd. | 2,160 | $61.0K | 0.00% | +2,160 | New |
| Tower Research Capital LLC (TRC) | 205 | $5.79K | 0.00% | +205 | New |
| Farther Finance Advisors, LLC | 40 | $1.13K | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 20 | $565 | 0.00% | +20 | New |
| Royal Bank of Canada | 6 | $0 | 0.00% | +6 | New |
| Steward Partners Investment Advisory, LLC | 0 | $0 | 0.00% | −1,910−100.0% | Sold out |
| Aspect Partners, LLC | 0 | $0 | 0.00% | −16−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −1−100.0% | Sold out |